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Heart failure (HF) is a complex disease involving multiple changes including 
cardiomyocyte hypertrophy (growth). Here we performed a set of screens in different HF 
and hypertrophy models to identify differentially expressed genes associated with HF 
and/or hypertrophy. Hypertensive Ren2 rats and animals with postmyocardial infarction 
(post-MI) HF were used as in vivo HF models, and neonatal rat cardiomyocytes treated 
with hypertrophy inducing hormones phenylephrine, endothelin-1, and isoproterenol were 
used as in vitro models. This combined approach revealed a robust set of genes that were 
differentially expressed both in vitro and in vivo. This included known genes like NPPA 
(ANP) and FHL1, but also novel genes not previously associated with hypertrophy/HF. 
Among these are PTGIS, AKIP1, and Dhrs7c, which could constitute interesting targets for 
further investigations. We also identified a number of in vivo specific genes and these 
appeared to be enriched for fibrosis, wounding, and stress responses. Therefore a number of 
novel genes within this in vivo specific list could be related to fibroblasts or other 
noncardiomyocytes present in the heart. We also observed strong differences between the 
two HF rat models. For example KCNE1 was strongly upregulated in Ren2, but not in post-
MI HF rats, suggesting possible etiology-specific differences. Moreover, Gene Ontology 
analysis revealed that genes involved in fatty acid oxidation were specifically down 
regulated in the post-MI group only. Together these results show that combining multiple 
models, both in vivo and in vitro, can provide a robust set of hypertrophy/HF-associated 
genes. Moreover it provides insight in the differences between the different etiology models 
and neurohormonal effects. 
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Heart failure (HF) is often the end-result of a number of cardiovascular diseases, 
including myocardial infarction, hypertension, and valve abnormalities. To maintain 
sufficient cardiac output under these conditions the heart adapts to these changes, a process 
called cardiac remodeling1. Cardiac fibrosis and hypertrophy are the two major processes 
driving cardiac remodeling. 
The initiating stimuli for cardiac hypertrophy can be broadly separated into 
biomechanical or stretch-sensitive mechanisms and neurohormonal mechanisms2. The latter 
include among others catecholamines (adrenaline and noradrenaline) and endothelin-1 (ET-
1), which bind to specific plasma-membrane receptors and activate intracellular signaling 
pathways2. Although these signaling pathways are inherently complex and involve 
significant cross talk, the common outcome, besides hormone-specific effects, is the 
induction of cardiomyocyte growth. This involves direct activation of protein synthesis and 
altered gene expression. A hallmark of cardiac hypertrophy is the activation of the so-called 
fetal gene program, which includes the re-expression of a number of fetal genes3. Important 
examples are atrial natriuretic peptide (ANP, NPPA) and brain natriuretic peptide (BNP, 
NPPB), and the latter is clinically used as an HF plasma marker4. 
Numerous global gene expression studies have been performed on human or animal 
heart tissue to identify genes that are differentially expressed during HF. Usually gene 
expression is compared between opposing pairs, such as nonfailing vs. failing hearts, and 
once it is performed it is essential to narrow down the large candidate gene lists. The gene 
sets of different studies only partly overlap, because of diversity in disease severity, 
etiologies, and microarray platforms5. Meta-analysis of gene expression studies has 
therefore identified some HF genes, including ANP, BNP, ACTC1 (alpha cardiac actin), 
and POSTN (periostin) but also revealed that most genes were only found in a limited set of 
studies5. Gene array studies have also been performed on cultured primary neonatal rat 
cardiomyocytes6-9, which are used as a general in vitro cardiomyocyte hypertrophy model. 
Compared with in vivo studies it has the advantage that it involves a relatively pure cell 
population, that there are no systemic effects present in the background, and that conditions 
can be well controlled. However, in vitro observations do not necessarily reflect in vivo 
changes. Also these studies generated large candidate lists that were not easily comparable, 
because of different platforms, time durations, and stimuli used6-9. 
As far as we know, no direct comparisons have been made between hypertrophy/HF-
induced in vitro and in vivo gene expression changes. This combination could provide a 
more robust outcome and, moreover, might identify in vitro and in vivo differences. We 
therefore treated neonatal rat ventricular cardiomyocytes (NRVCs) with hypertrophy 
stimulating agents phenylephrine (PE, α-adrenergic), isoproterenol (Iso, β-adrenergic), and 
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ET-1. In addition we used two different HF models, namely Ren2 rats that overexpress 
mouse renin generating hypertension and resulting in HF, and we used a rat post-MI model. 
Our results show overlap between the models and identified some potential novel 
hypertrophy/HF-associated genes. In addition interesting differences between the different 
models and conditions were observed. 
2. MATERIALS AND METHODS 
2.1. Reagents and chemicals 
Cell culture medium and serum were obtained from Lonza Benelux (Breda, The 
Netherlands), penicillin-streptomycin and trypsin were from Invitrogen (The 
Netherlands). L-[4,5-3H]-Leucine (37 MBq/ml, 5,85 TBq/mmol) was from GE Healthcare 
Europe (Diemen, Belgium), and Ultima Gold XR scintillation liquid was from Perkin 
Elmer (Groningen, The Netherlands). Unless otherwise stated all chemicals were purchased 
at the highest possible grade from Sigma-Aldrich Chemie (Zwijndrecht, The Netherlands). 
2.2. Cardiomyocyte isolation and culturing 
NRVCs were isolated from the cardiac ventricles of one- to three-day-old Sprague-
Dawley (SD) pups after decapitation, as previously described10. In short, hearts were 
removed from the thoracic cavity and ventricular tissue fragments were repeatedly treated 
with 2 mg/ml trypsin to release the cells. To remove noncardiomyocytes, isolated cells 
were preplated in cell culture dishes in 50 ml MEM with 5% FCS for 45 min. During this 
period, most noncardiomyocytes (mainly fibroblasts) attached to the dish, whereas 
cardiomyocytes remained in solution. The cardiomyocytes were subsequently transferred to 
separate tissue culture dishes and allowed to attach. NRVCs were cultured at 37°C under 
5% CO2 in DMEM and supplemented with 10% FCS and penicillin-streptomycin (100 
IU/ml and 100 µg/ml, respectively), as described previously10. For experiments in which 
cells were treated with hypertrophy-inducing agents, cells were first serum starved for 24 h. 
Cells were then treated 24 h with either 50 µM PE, 10 µM Iso, or 10 nM ET-1. 
2.3. Animal experiments 
We used male TGR(mRen2)27 (Ren2) rats that were homozygous for the expression of 
the mouse renin (Ren)-2 transgene (Max Delbrück Center for Molecular Medicine, Berlin-
Buch, Germany)11,12. SD rats were used as controls. Animals were fed ad libitum. Ren2 rats 
and control rats were killed at 13 wk of age13. In parallel, HF was induced in SD rats by 
permanent ligation of the left coronary artery to produce a myocardial infarction (MI)14,15. 
Anesthetic agents used: isoflurane (5% induction, 2.5% maintenance with oxygen) and 


























proper anesthesia was confirmed by reflex analysis and by heart rate monitoring. 
Analgesics used: buprenorphine 0.04 mg/kg, every 8 h for 3 days. Control rats underwent a 
sham operation. Nine weeks later, MI animals were killed. All animals were killed under 
general anesthesia, as described above, by heart removal. Myocardial tissues from all 
groups were snap frozen for molecular analyses. From the post-MI animals remote 
noninfarcted cardiac tissue was used for analysis. All animal studies were conducted in 
accordance with the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals and were submitted to, and approved by, the Committee for Animal Experiments 
of the University of Groningen. 
2.4. Quantitative real-time PCR 
Relative gene expression of ANP, cyclophilin-1, and GAPDH was determined by 
quantitative real-time PCR (RT-PCR) on a Bio-Rad CFX384 real-time system using SYBR 
Green dye, as described before16. Gene expression was determined by correcting for 
reference gene values (cyclophilin A or GAPDH), and the calculated values were expressed 
relative to the control group per experiment. Primer sequences of ANP and cyclophilin A 
have been described before10. GAPDH sequences are: GAPDH-forward, catcaagaaggtggtga 
agc; GAPDH-reverse, accaccctgttgctgtag. 
2.5. L-[4,5-3H]-Leucine incorporation assay 
Cardiomyocytes were grown in 12-well plates and subsequently starved for 24 h in 
DMEM containing starvation medium lacking FCS. Subsequently, L-[4,5-3H]-leucine was 
added to all wells either in the presence or in the absence of 50 µM PE, 10 µM Iso, or 10 
nM ET-1. Cells were cultured for an additional 24 h, and radioactivity incorporation was 
determined as described before10. 
2.6. Microarray sample preparation and analysis 
Total RNA from the cells or tissue was extracted using the Nucleospin RNA II kit 
(Macherey-Nagel, Düren, Germany). RNA quality was checked using the Agilent 2100 
Bioanalyzer and subsequently prepared for microarray analysis using the standard Illumina 
TotalPrep-96 RNA Amplification Protocol (Ambion). Samples were exponentially 
amplified from a starting amount of 50 ng to a final amount of 1 µg purified biotin-labeled 
cRNA using the Illumina TotalPrep-96 RNA Amplification Kit (Ambion). This final cRNA 
was evaluated, and the quality, concentration, and size of the reaction productions were 
measured using the Agilent RNA 6000 Nano Kit (Agilent). Illumina RatRef-12 Beadchips 
were used for microarray analysis. Chips were scanned using the BeadXpress Reader 
(Illumina). Beadstudio Illumina was used to import the raw data and remove any 
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background noise. Data were converted to standard format and exported for use in Agilent 
Genespring GX (version 11.0, Agilent). We used Genespring to perform quantile 
normalization on each individual well and further analysis of the data. The MIAME 
standard for microarray data was followed, and all data were submitted to the CIBEX 
database (accession codes: CBX250 and CBX251). 
2.7. Statistical analysis 
All data are expressed as means ± SE. The differences between two groups were 
determined by a Student's test. Comparisons between more than two groups of data were 
assessed by one-Way ANOVA followed by Bonferroni's post hoc test. For nonparametric 
distributed data the Mann-Whitney U-test was used. Gene Ontology (GO) and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed with 
Bonferroni adjustment and a minimal threshold of 3 genes. A value of P < 0.05 was 
considered significant. 
2.8. Supplemental Data Lists 
Supplemental Data Lists can be found online: http://physiolgenomics.physiology.org/ 
content/44/8/443/suppl/DC1. 
3. RESULTS 
3.1. In vivo rat HF models for gene expression analysis 
To identify genes that are differentially expressed during hypertrophy and HF 
development, we used a combined in vitro/in vivo gene array approach. For the in vivo 
analysis two different animal HF models were compared with their respective control 
groups. One group consisted of transgenic Ren2 rats (n = 4), which overexpress mouse 
renin, resulting in hypertension and consequently HF development11,12. These animals were 
compared with SD rats, which comprise the genetic wild-type background (n = 5). In the 
other rat model an MI was induced by permanent ligation of the left coronary artery 
resulting in MI. These animals were killed 9 wk post-MI together with the sham-operated 
animals (n = 5, 4). In the Ren2 group significant worsening of cardiac function [contraction 
(+dp/dtmax) and relaxation (−dp/dtmin)] could be observed, and a similar trend was 
observed in the post-MI group (Table 1). Also blood pressure dropped in the Ren2 and 
post-MI group. In the monogenetic Ren2 model these values were significantly different 
from the control, but this was not the case for the more heterogeneous post-MI model. This 
is related to the relative small sample size used for the gene array study, since functional 
parameters were significantly different in the larger group size15. Most importantly, with 


























respect to gene expression, a significant increase of cardiac ANP expression, a marker for 
HF, was observed in both the Ren2 and post-MI groups (Figure 1A and 1B). 
Table 1. Baseline characteristics of rat HF models 
 SD REN2* MI-sham MI 
n 5 4 4 5 
SBP, mmHg 112 ± 3 93 ± 4 122 ± 2 110 ± 4 
DBP, mmHg 80 ± 4 65 ± 3 81 ± 2 76 ± 2 
MAP, mmHg 91 ± 4 74 ± 3 95 ± 2 88 ± 4 
HR, beats/min 384 ± 36 309 ± 13 342 ± 15 328 ± 12 
LVEDP, mmHg 2.8 ± 0.5 7.3 ± 1.4 8.3 ± 2.3 14.2 ± 4.7 
dPdtmax, mmHg/s 8534 ± 392 5202 ± 178 11147 ± 1205 8785 ± 696 
dPdtmin, mmHg/s -10434 ± 745 -5178 ± 271 -9461 ± 1776 -7821 ± 769 
HW/BW, mg/g 3.29 ± 0.11 5.06 ± 0.05 3.65 ± 0.40 4.21 ± 0.43 
HW, mg 1181 ± 37 1535 ± 60 1630 ± 190 1668 ± 199 
Data are presented as means ± SE. HF, heart failure; SD, Sprague-Dawley; MI, myocardial infarction; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate; LVEDP, left 
ventricular end diastolic pressure; dPdtmax and dPdtmin are indexes of maximal contraction and relaxation; BW, 
body weight; HW, heart weight. *All values were significantly different (P < 0.05) from SD, except for HR. 
 
Figure 1. Confirmation of the in vivo and in vitro hypertrophy/heart failure (HF) models. A: RT-PCR 
on cDNA from Ren2 rats (n = 5) with HF and as a control on Sprague-Dawley (SD) rats (n = 4 for each 
group). Atrial natriuretic peptide (ANP) expression is shown relative to GAPDH levels. B: RT-PCR on 
cDNA from postmyocardial infarction (post-MI) HF and sham-operated rats (n = 4 for each group). ANP 
expression is shown relative to GAPDH levels. C: primary neonatal rat cardiomyocytes were cultured for 24 
h in serum-free medium and subsequently stimulated with phenylephrine (PE), isoproterenol (Iso), or 
endothelin-1 (ET-1). After 24 h stimulation in the presence of L-[4,5-3H]-leucine the radioactive 
incorporation in cellular protein was analyzed by liquid scintillation counting. Values are relative to the 
respective nontreated cultures (n = 4 for each group). D: ANP expression in the different cardiomyocyte 
cultures was determined by RT-PCR and corrected for cyclophilin A expression (n = 4). Ren2, 




3.2. In vitro cardiomyocyte hypertrophy models 
The in vitro hypertrophy model consisted of cultures of primary isolated NRVCs, 
which were exposed to three different hypertrophy-inducing agents (n = 4 in each group, 
PE n = 3). As determined by L-[4,5-3H]-leucine incorporation (protein synthesis), treatment 
with PE and ET-1 generated a strong hypertrophic response, whereas Iso induced a modest 
increase (Figure 1C). A similar trend was observed for ANP gene expression, which was 
strongly elevated after PE and ET-1 treatment and only modestly elevated after Iso 
treatment (Figure 1D). Together, this shows that these treatments trigger hypertrophy and 
fetal gene expression in cardiomyocytes in vitro. 
3.3. Gene array analysis animal models 
Whole genome gene expression in the cardiac animal samples and of the 
cardiomyocyte cultures was analyzed using Illumina RatRef-12 Beadchip arrays. Only 
those genes that showed a significant 1.5-fold change in gene expression (P < 0.05) 
compared with their respective control groups were selected. This yielded 159 differentially 
expressed genes in the Ren2 group and 254 differentially expressed genes in the MI group. 
Subsequently, the overlap in both HF groups was analyzed, yielding only a small set of 58 
genes (16%) that were similarly up- or downregulated in both groups (Figure 2A).  
 
Figure 2. Venn diagrams of the number of differentially expressed genes identified in the different 
groups. A: differential gene expression in different groups was determined as described in the text. Shown 
are differentially expressed genes in Ren2 and post-MI animals compared with their respective controls. B: 
differentially expressed genes identified after stimulation for 24 h with PE, Iso. or ET-1. C: differentially 
expressed genes present in at least in 2 in vitro models were compared with the differentially expressed genes 
present in at least 1 in vitro model. An overlap of 62 genes was identified. 
Since genes that are just above selection threshold in one group might be missed in the 
other group this representation could give a biased view. Therefore, we also analyzed 
whether the top 10 up- and downregulated genes in the Ren2 and MI groups showed a 
similar distribution. As can be seen from Table 2, this is indeed the case. Within this top 10, 


























several common HF markers, including POSTN17 and ANP4, were similarly upregulated in 
both animal groups. It is remarkable, however, that the strongest upregulated gene in the 
Ren2 group, KCNE1 (potassium channel, voltage-gated, ISK-related subfamily, member 1) 
was not upregulated in the MI group. This was also true for RGD1562305 (SBSN, 
suprabasin), although the latter did show a significant increase in the post-MI model by RT-
PCR, albeit much smaller than in the Ren2 rats (Figure 3). In the MI group CA3 (carbonic 
anhydrase 3) was strongly upregulated, but this could not be confirmed by RT-PCR (Figure 
3). The full gene tables are presented in Supplemental Data List 1. 
Table 2. Top 10 genes with highest up- or downregulation in at least one in vivo model (1.5-fold, P < 0.05) 
Gene Genbank ID Protein Regulation Ren2 MI 
CA3* 54232 carbonic anhydrase III up  47.71 
WISP2 29576 WNT1 inducible signaling pathway 
protein 2 
up  28.79 
LTBP2 59106 latent transforming growth factor beta 
binding protein 2 
up 8.64 24.93 
KCNE1 25471 potassium voltage-gated channel, Isk-
related family, member 1 
up 24.67  
RGD1562305 
(SBSN) 
292793 suprabasin up 16.09  
THBS4 29220 thrombospondin 4 up  14.15 
POSTN 361945 periostin, osteoblast specific factor up 8.82 13.50 
SDPR 316384 serum deprivation response up 11.17  
PRG4 289104 proteoglycan 4 up  10.88 
ANP 24602 atrial natriuretic peptide up 9.39 5.96 
RT1-A1 24973 RT1 class Ia, locus A1 down 20.52  
RGD1561381 498340 similar to microsomal glutathione S-
transferase 3 
down 20.29  
RPS9 81772 ribosomal protein S9 down 19.53  
LOC498989 498989 similar to Ab2-143 down 13.85  
RGD1564649 367102 similar to 40S ribosomal protein S9 down 11.94  
USMG5 171069 upregulated during skeletal muscle growth 
5 homolog 
down 11.78  
VEGFB 89811 vascular endothelial growth factor B down 9.52  
MRLP17 171061 mitochondrial ribosomal protein L17 down 7.39  
SLC3a1 29484 solute carrier family 3, member 1 down 4.24  
RPS9 81772 ribosomal protein S9 down 4.06  
No value given indicates absence of significant up- or downregulation. Ren2, n = 4; SD, n = 5; MI, n = 5; sham, n 
= 4. *Could not be confirmed by RT-PCR. See also Figure 3K. 
3.4. In vitro cardiomyocyte hypertrophy models 
Whole genome gene expression of the hypertrophy-induced cardiomyocyte cultures 
was compared with the untreated culture group. This revealed that 415, 170, and 321 genes 
were differentially expressed after PE, ET-1, and Iso treatment respectively (P < 0.05, >1.5-
fold difference) (Figure 2B). Thus both adrenergic stimuli (PE and Iso) gave a stronger 
hypertrophic effect than ET-1, even though hypertrophy development with Iso was less 
pronounced compared with ET-1 (Figure 1C). Comparison of these data sets showed a 
common overlap of 71 genes. A list of the 10 most upregulated genes present in at least two 
conditions is presented in Table 3. Most of the top 10 genes were upregulated by all three 
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stimuli and include known cardiac disease genes, like Xirp2, Scn3b, and ACTC1. Although 
HF markers, like ANP and BNP, were not present in this top these are present in the full 
gene list (Supplemental Data List 2). It is remarkable that the strongest upregulated gene, 
PNOC (prepronociceptin), was specific for PE and Iso stimulation. In addition, the 
potassium voltage-gated channel KCND2 was upregulated only in ET-1-treated cells, and 
the aldo-keto reductase gene AKR1B8 was specific for Iso stimulation. Most 
downregulated genes were specific for adrenergic stimulation (Iso and/or PE), including the 
strongly downregulated short chain dehydrogenase/reductase gene Dhrs7c. Only one gene 
of the top 10 genes was downregulated by all three stimuli, ANGPT2 (angiopoietin 2), a 
protein involved in vascular remodeling18. 
Table 3. Top 10 genes with highest up- or downregulation in at least one in vitro model (>1.5-fold, P < 0.05) 
Gene Genbank ID Protein Regulation ET-1 Iso PE 
PNOC 25516 prepronociceptin up  28.35 42.36 
WFDC1 171112 WAP four-disulfide core domain 
1 
up 3.89 5.30 11.05 
Scn3b 245956 sodium channel, voltage-gated, 
type III, beta 
up 4.37 4.98 6.82 
Xirp2 497771 xin actin-binding repeat 
containing 2 
up 4.14 3.29 5.85 
INHA 24504 inhibin alpha up 2.13 4.48 5.62 
ACTC1 29275 actin, alpha, cardiac muscle 1 up 3.37 3.37 5.05 
RGD1560242 499334 similar to RIKEN cDNA 
1700028P14 
up 1.83 3.69 4.84 
AKR1B8 286921 aldo-keto reductase family 1, 
member B8 
up  4.55  
KCND2 65180 potassium voltage-gated 
channel, shal-related subfamily, 
member 2 
up 4.31   
RND1 362993 Rho family GTPase 1 up 2.06 3.91 4.25 
Dhrs7c 287411 dehydrogenase/reductase (SDR 
family) member 7C 
down  20.18 4.12 
LOC501066 501066 Unknown down  6.31  
CXCL11 305263 chemokine (C-X-C motif) ligand 
11 
down  5.56 3.17 
Asb11 302666 ankyrin repeat and SOCS box 
containing 11 
down  4.81 2.04 
PTPRR 94202 protein tyrosine phosphatase, 
receptor type, R 
down  4.79 4.58 
Angpt2 89805 angiopoietin 2 down 1.92 4.01 4.66 
CITED1 64466 Cbp/p300-interacting trans-
activator with Glu/Asp-rich 
carboxy-terminal domain 1 
down  3.75 1.96 
V-ATPase S1 361875 ATPase, H_ transporting, 
lysosomal accessory protein 1 
down  3.66  
RXRG 83574 retinoid X receptor gamma down  3.47 3.12 
CXCL10 245920 chemokine (C-X-C motif) ligand 
10 
down  3.30  
No value given indicates absence of significant up- or downregulation. Control, n = 4; endothelin-1 (ET-1), n = 4; 
isoproterenol (Iso), n = 4; phenylephrine (PE), n = 3. 
 


























3.5. Comparison of the in vitro and in vivo data sets 
To compare the in vitro data with the in vivo data all differentially in vitro expressed 
genes that were present in at least two conditions (253 genes) were compared with all 
differentially in vivo expressed genes (355 genes). This yielded a set of 62 genes 
differentially expressed in at least two in vitro and one in vivo model (Figure 2C). Within 
the group of 62 genes, established hypertrophy/HF markers like ANP and BNP and a 
promising new HF marker LGALS3 (galectin-3) were present19,20. Based on the average 
fold change gene expression we made a list of the top 10 up- and downregulated genes 
found in at least two in vitro models and one in vivo model (Table 4). In this list, a number 
of known HF markers and cardiac disease genes are present, like ANP, XIRP2, CSRP2, 
FHL1, TIMP1, and LGALS3. However, it also includes novel upregulated genes like 
AKIP1 (also termed BCA3 or C11Orf17), PTGIS, and downregulated genes, like DHRS7c 
(Table 4). We also identified a large number of genes that showed differential expression in 
vitro, but not in vivo and vice versa (Table 5 and Supplemental Data List 3). 
Table 4. Top 10 genes with highest up- or downregulation in at least two in vitro models and at least one in 
vivo model (1.5-fold, P < 0.05) 
Gene Entrez ID Protein Regulation Mean score 
Xirp2/LOC497771 497771 xin actin-binding repeat containing 2 up 3.97 
ANP 24602 atrial natriuretic peptide up 3.95 
CSRP2 29317 cysteine and glycine-rich protein 2 up 2.77 
PTGIS 25527 prostaglandin I2 (prostacyclin) 
synthase 
up 2.66 
C11Orf17 361624 A kinase (PRKA) interacting protein 1 
(AKIP1) 
up 2.48 
FHL1 25177 four and a half LIM domains 1 up 2.44 
TIMP1 116510 tissue inhibitor of metalloproteinase 1 up 2.42 
TNFRSF12a 302965 tumor necrosis factor receptor 
superfamily, member 12A 
up 2.13 
AVPI1 171386 arginine vasopressin-induced 1 up 2.11 
LGALS3 83781 lectin, galactoside-binding, soluble, 3 up 1.99 
ENAH 360891 enabled homolog (Drosophila) up 1.98 
Dhrs7c 287411 dehydrogenase/reductase (SDR 
family) member 7C 
down 6.21 
CXCL11 305236 chemokine (C-X-C motif) ligand 11 down 2.92 
RXRG 83574 retinoid X receptor gamma down 2.37 
SLC4a1ap 298805 solute carrier family 4 (anion 
exchanger), member 1, adaptor protein 
down 2.06 
SLC2a4 25139 solute carrier family 2 (facilitated 
glucose transporter), member 4 
down 1.95 
LRP16 246233 MACRO domain containing 1 down 1.71 
PINK1 298575 PTEN induced putative kinase 1 down 1.68 
CABC1 360887 chaperone, ABC1 activity of bc1 
complex like (S. pombe) 
down 1.66 
HADHSC 113965 hydroxyacyl-CoA dehydrogenase down 1.63 
ECH1 64526 enoyl CoA hydratase 1, peroxisomal down 1.60 





Figure 3. Confirmation of gene expression profiles by RT-PCR in the in vivo models. Expression of 
indicated genes was determined by RT-PCR on rat heart cDNA from sham (n = 7) and post-MI (n = 8) rats 
and from control SD (n = 8) and Ren2 rats (n = 8). A, B: PTGIS; C, D: XIRP2; E, F: POSTN; G,H: KCNE1; 
I, J: SBSN; K, L: CA3. *P <0.05 compared with the respective control. 
3.6. Confirmation of gene expression changes 
To confirm our gene array data we performed gene expression analysis by quantitative 
real-time PCR of a selected number of identified genes in post-MI and Ren2 rats. First, we 
analyzed expression of Xirp2 and PTGIS, which were upregulated both in in vitro and in 
vivo models (Table 4). Like ANP, PTGIS was significantly upregulated in post-MI rats and, 
albeit just not significant, also in Ren2 animals, whereas Xirp2 was significantly 
upregulated in the Ren2 model only (Figure 3A-3D). In vitro, both genes were clearly 
upregulated with adrenergic stimulation and to a lesser extent also with ET-1 (Figure 
4A and 4B). These data are largely in concert with the gene array data. We also analyzed 
some genes that were only upregulated in the in vivo models. As shown in Figure 
3E and 3F, POSTN was significantly upregulated in both models, and KCNE1 was strongly 
upregulated only in the Ren2 model, in accordance with the gene array data. SBSN, was 
strongly upregulated in the gene array in Ren2 animals, and this could be reproduced by 


























RT-PCR (Figure 3I). However, it also revealed a much smaller, but significant upregulation 
in MI animals (Figure 3J), which was missed in the gene array. CA3, on the other hand, 
was, according to the gene array data, highly upregulated in the MI model, but this could 
not be confirmed by the RT-PCR. A large variation in CA3 expression between the animals 
was observed, and the small sample size used in the gene array may explain why it was 
accidently picked up. POSTN and SBSN were not regulated in vitro by hypertrophic 
stimuli (Figure 4C and 4E), in agreement with the gene array data. We also tested 
expression of PNOC, a gene that was strongly induced by adrenergic stimulation in vitro. 
We could confirm this observation by RT-PCR (Figure 4F) and also tested expression of 
PNOC in our animal models but could not detect any expression of this gene. 
 
Figure 4. Confirmation of gene expression profiles by RT-PCR in the in vitro models. Expression of 
indicated genes was determined by RT-PCR on cDNA from primary cultured neonatal rat heart 
cardiomyocytes treated with PE, Iso, and ET-1, or left untreated (control) (n = 5 for each condition). A: 
PTGIS; B: XIRP2; C: POSTN; D: KCNE1; E: SBSN; F: PNOC. *P < 0.05 compared with the control. 
We therefore decided to compare the expression of the above-mentioned genes in 
neonatal and adult hearts, to see whether additional baseline differences were present 
between neonatal and adult heart tissue. As shown in Figure 5A-5F, the expression of 
PTGIS, POSTN, KCNE1, SBSN, and PNOC was all significantly higher in neonatal tissue 
compared with adult tissue. The only exception was Xirp2, which was higher in adult tissue, 
albeit not significantly. Finally, we also tested expression of several genes (including 
LOXL1 and NUPR1) in cultured neonatal cardiac fibroblasts treated with PE, Iso, and ET-1. 
Except for POSTN and SBSN, which showed some increased expression after PE treatment, 
no changes were observed in these fibroblasts (data not shown). This confirms that all 
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changes we observed in our in vitro system were cardiomyocyte specific. Of course it does 
not exclude that in neonatal cardiac fibroblasts these genes may be regulated by other 
stimuli. 
Table 5. Top 10 genes with highest up- or downregulation specific for at least two in vitro conditions or 
specific for the in vivo conditions only 
In Vitro Only  In Vivo Only 
Gene Entrez ID Regulation  Gene Entrez ID Regulation 
PNOC 25516 up  LTBP2 59106 up 
SCN3b 245956 up  POSTN 361945 up 
INHA 24504 up  NUPR1 113900 up 
ACTC1 29275 up  FN1 25661 up 
RGD1560242 499334 up  SERPINE2 29366 up 
RND1 362993 up  LOXL1 315714 up 
MYBPC2 292879 up  MGC72614 310540 up 
IFIT1 294090 up  MFAP5 362429 up 
YIP1B 364147 up  CTGF 64032 up 
SLPI 84386 up  ANXA2 56611 up 
ANGPT2 89805 down  TXN2 79462 down 
PTPRR 94202 down  ACAT1 25014 down 
ASB11 302666 down  PFKM 65152 down 
LOC191574 191574 down  ALDH5a1 291133 down 
Adhfe1 362474 down  LDHD 307858 down 
CXCL13 498335 down  ISOC1 364879 down 
RGD1562717 363767 down  NDE1 83836 down 
SMOC2 292401 down  SESn1 294518 down 
CITED1 64466 down  GOT2 25721 down 
PTN 24942 down  RGD1565358 314759 down 
All listed genes with (> 1.5-fold change and P < 0.05). 
 
Figure 5. RT-PCR expression analysis of a selected number of genes in neonatal and adult heart. 
Expression of indicated genes was determined by RT-PCR on cDNA from neonatal and adult rat hearts (n = 
6 for each condition). A: PTGIS; B: XIRP2; C: POSTN; D: KCNE1; E: SBSN; F: PNOC. *P < 0.05 
compared with the neonatal expression. 


























3.7. GO analysis 
Finally, we performed GO on the different data sets using Genetrail and complemented 
this with KEGG pathway analysis. Both Tables 6 (GO analysis) and 7 (KEGG pathways) 
show that there are strong differences between the in vitro data sets on one hand and the in 
vivo data sets on the other hand. Full data sets can be found in Supplemental Data Lists 4 
and 5. GO analysis revealed significant induction of genes involved in sterol and 
cholesterol metabolism in vitro, but not in the in vivo models (Table 6). Also myofibril and 
contractile fiber groups were upregulated in the in vitro, but not in vivo data sets. 
Oxidoreductase activity-encoding genes were only upregulated in the Iso-treated cells. In 
the in vivo data sets the extracellular proteins, in particular matrix-encoding genes like 
LTBP, POSTN, fibronectin (FN1), and LOXL1, were highly upregulated. In addition in the 
in vivo models, mitochondrial proteins were downregulated, indicative for changes in 
metabolism in vivo. Surprisingly, only in the MI model fatty acid and lipid oxidation were 
downregulated at the gene expression level.  
Table 6. GO analysis of in vitro- and in vivo-specific genes 
 In Vitro  In Vivo 
GO Category PE Iso ET-1  Ren2 Post-MI 
 Upregulated genes    
Cholesterol metabolic process 8.33 e-8 3.06 e-3 1.80 e-6    
Sterol metabolic process 1.00 e-7 3.39 e-3 2.03 e-6    
Cholesterol biosynthetic process 2.38 e-6 5.31 e-3 7.47 e-8    
Sterol biosynthetic process 2.38 e-6 5.31 e-3 7.47 e-8    
Developmental process 8.89 e-7  3.36 e-2  1.73 e-2 2.76 e-4 
Myofibril 5.91 e-3 3.43 e-3 1.62 e-6    
Contractile fiber 1.83 e-3 7.72 e-3 4.26 e-6    
Oxidoreductase activity  5.67 e-5     
Extracellular region     1.90 e-7 1.83 e-33 
Extracellular matrix     7.73 e-8 1.43 e-27 
Response to wounding      2.15 e-6 
Response to stress     3.48 e-2 8.02 e-5 
 Downregulated genes    
Extracellular region 5.53 e-4 8.14 e-8 4.18 e-5    
Mitochondrion     2.35 e-8 2.37 e-25 
Cytoplasm     1.01 e-5 5.25 e-14 
Organelle     4.97 e-5 3.79 e-7 
Fatty acid metabolism      4.08 e-12 
Lipid oxidation      4.85 e-12 
Organic and carboxylic acid 
catabolic process 
     1.25 e-10 
Oxidoreductase activity      4.21 e-6 
Only selected main gene families are shown that were highly significantly up- or down-regulated in at least one 
model with a p < 1.0 e-3. 
Similar results were obtained in the KEGG pathway analysis, which clusters genes to 
specific pathways (Table 7). Again steroid and terpenoid biosynthesis pathways were 
strongly upregulated in vitro. Especially in PE- and ET-1-treated cells, nearly all genes of 
these pathways, which together are involved in sterol, cholesterol, and steroid biosynthesis, 
Chapter 3 
 58
were upregulated (Figure 6). In Iso-treated cells glutathione metabolism was upregulated, 
again pointing toward oxidative stress. In vivo, signaling proteins interacting with the 
extracellular matrix were upregulated. Metabolic genes were downregulated in the in vivo 
models and fatty acid metabolism only in the MI model. 
Table 7. Pathways of genes significantly up- or downregulated in the different models 
 In Vitro  In Vivo 
KEGG Category PE Iso ET-1  Ren2 Post-MI 
 Upregulated genes    
Steroid biosynthesis 2.55 e-10 1.74 e-7 3.83 e-8    
Terpenoid synthesis 6.36 e-7  4.87 e-6    
Glutathione metabolism  3.83 e-5     
Drug metabolism (p450)  9.03 e-4     
Focal adhesion     2.39 e-2 6.06 e-4 
ECM-receptor 
interaction 
     1.59 e-6 
 Downregulated genes    
PPAR signaling 1.50 e-2     1.97 e-4 
Butanoate metabolism     7.55 e-2 8.04 e-4 
Amino acid metabolism     3.36 e-2 3.69 e-4 
Fatty acid metabolism      2.35 e-10 
Metabolic pathways      6.12 e-6 
Peroxisome metabolism      1.47 e-5 
Only pathways that were at least identified in one model with a P value < 1.0 e-3 are shown. 
4. DISCUSSION 
Cardiomyocyte growth (hypertrophy) is one of the hallmarks of HF development1,2. 
Here we investigated gene expression profiles of in vitro cultured cardiomyocytes treated 
with hypertrophy-inducing agents (PE, ET-1, and Iso) and in vivo HF models (hypertensive 
Ren2 rats and post-MI rats). This approach yielded large data sets of differentially 
expressed genes. By overlapping them we obtained a concise set of genes, including 
numerous known HF markers. Interestingly, this set also included a number of interesting 
genes not linked to hypertrophy/HF before and revealed striking difference between in vitro 
and in vivo models. 
Analysis of differential gene expression in cardiomyocytes stimulated with 
hypertrophy-inducing agents and in two rat HF models generated large lists of differentially 
expressed genes. By combining these expression data sets we obtained a concise list of 62 
differentially expressed genes. This list included most known HF markers, including ANP, 
BNP, TIMP1, FHL1, SGAL3 (Table 4), indicating that this is a powerful approach to 
identify differentially expressed genes that are linked to hypertrophy and HF development. 
This list also comprised genes that have recently been linked to cardiac remodeling, like 
TNFRSF12a (also termed Fn14)21, indicating that this approach could uncover new HF 
genes. In fact this list contained a number of genes that have previously not been linked to 
hypertrophy and HF development. This list includes PTGIS (also termed PGIS, CYP8), a 
gene for which MI, hypertension, and stroke-associated polymorphisms have been 


























identified by genome-wide association studies22. PTGIS encodes a prostacyclin synthase 
and is a key enzyme in the synthesis of prostacyclin (PGI2), which is an inhibitor of platelet 
aggregation and a short-acting vasodilator and can contribute to the development of stroke, 
MI, and atherosclerosis23. Moreover, mouse PGI2 receptor knockout mice develop cardiac 
hypertrophy and fibrosis24. Other interesting genes include AKIP1, an adaptor protein in the 
PKA-NFκB pathways25,26, and the short chain dehydrogenase/reductase Dhrs7c, which is 
downregulated in most models. This downregulation of Dhrs7c has in the meantime also 
been confirmed in cardiac biopsies from HF patients, also at the protein level27. Our 
inventory could therefore be an important starting point for the investigation of novel genes 
associated with HF. 
 
Figure 6. Terpenoid and steroid biosynthesis pathways. Differentially expressed genes identified in our in 
vitro models are marked in red. 
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Our investigations also revealed clear differences between in vitro and in vivo 
experiments (Tables 5-7). GO and KEGG pathway analysis revealed a strong enrichment of 
genes involved in the steroid biosynthetic pathway that are specifically upregulated in vitro 
after hypertrophic stimulation, but not in vivo. Since these pathways are essential for the 
novo cholesterol synthesis, it might suggest that there is an increased requirement for 
cholesterol during hypertrophic growth of cardiomyocytes. In the in vivo models a strong 
enrichment for extracellular matrix and stress-specific genes was observed. This included 
the highly expressed genes LTBP, POSTN, FN1, and LOXL1, which are predominantly 
expressed by fibroblasts or other noncardiomyocytes in the heart and explains the absence 
in the in vitro cardiomyocyte experiments. The in vivo-specific list may therefore contain 
differentially expressed HF genes that are specific for noncardiomyocytes, and novel genes 
within this list, like MGC72614 (FAM198B), may therefore be linked to fibrotic or stress-
related processes. Also within the in vitro and in vivo models striking differences were 
observed. In vitro, for example oxidative stress appeared to be increased after Iso treatment 
as extrapolated from the increased expression of oxidoreductase and glutathione metabolic 
genes. This is in line with papers describing activation of oxidative stress pathways in 
cardiomyocytes after beta adrenergic stimulation28. In our post-MI model, genes related to 
the wounding response were upregulated, but not in our Ren2 model; this is most likely 
related to the severe myocardial damage in the MI model. Fatty acid metabolic genes were 
downregulated in the post-MI model, in line with the substrate shift from fatty acids to 
glucose that occurs during HF development29,30. Surprisingly, however, this change was not 
observed in our monogenetic Ren2 rat model, with hypertension, which had at least the 
same extent of hypertrophy/HF development. This suggests that this substrate shift is not 
obligatorily linked to hypertrophy development but might be associated with the respective 
different etiologies that contribute to HF development. 
We performed RT-PCR on a selected set of genes identified in the array and could 
confirm differential expression of most genes. Only CA3, which appeared to be highly 
upregulated in the MI model, could not be replicated and showed similar, but highly 
variable expression in all groups. On the other hand we could confirm the specific 
upregulation of KCNE1 in the Ren2 model. This might be indicative for etiologic 
differences, although we cannot exclude the possibility that it is dependent on the severity 
of the disease. SBSN (RGD1562305) expression was strongly increased in the Ren2 group, 
and also an increase in the MI group could be observed. This gene was not upregulated in 
cardiomyocytes after hypertrophy stimulation in vitro but did show some increased 
expression in PE-treated fibroblasts, suggesting that it might be more fibroblast related. 
This extracellular protein was originally suggested to play a role in striated epithelia31 but 
was recently also shown to be strongly induced in muscle of exercised dogs32. Together 
with our observation, this may suggest that SBSN also plays a role in heart and muscle 


























function under stress-related conditions. It might therefore be rewarding to investigate 
plasma levels of this secreted protein in HF patients. 
Several features of the experiments are important in the interpretation of the present 
data. First we used neonatal rat cardiomyocytes for in vitro hypertrophy and compared 
these data with in vivo adult rat HF models. Therefore some of the differences between the 
in vitro and in vivo data could be related to the age of the cells, neonatal vs. adult. Indeed 
we could observe baseline differences between neonatal and adult hearts, and PNOC 
expression, for example, was absent in adult tissue. We made the choice for neonatal rat 
cardiomyocytes, because these cells are used as an established model for in vitro 
cardiomyocyte hypertrophy. Our results show, however, some important differences 
between this in vitro model and the in vivo situation. Some differences could be related to 
the timing of the experiments. In vitro hypertrophy induction only lasted 24 h, and therefore 
some of the changes might be related to early responses in contrast to the in vivo 
experiments. Some of the effects might also be temporal or related to the severity of HF 
and hence be present in one, but not the other group. As with most screens we also missed 
some known HF-associated genes, like SERCA2a, indicating that although comprehensive 
the generated lists are not complete. 
In conclusion, we have identified a comprehensive set of genes that are differentially 
expressed in in vitro cardiomyocyte models for hypertrophy and in animal HF models. This 
list includes a large number of genes known to be associated with HF, as well as potential 
new targets, like AKIP1, for future analysis. Furthermore, we have identified a large 
number of genes that appear to be specific for particular conditions. This stresses again that 
we have to be careful with extrapolations from one to another model or condition. These 
datasets should prove invaluable for a further analysis of cardiac diseases in particular 
pathological hypertrophy and HF development. 
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